| Glucose metabolism | R-HSA-70326 | 6.77 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 6.11 |
| Cell Cycle | R-HSA-1640170 | 3.89 |
| Developmental Biology | R-HSA-1266738 | 3.48 |
| Signaling by VEGF | R-HSA-194138 | 4.66 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 4.32 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 6.47 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 8.89 |
| Signaling by EGFR | R-HSA-177929 | 4.59 |
| AXIN mutants destabilize the destruction complex, activating WNT signaling | R-HSA-4839735 | 9.18 |
| Platelet homeostasis | R-HSA-418346 | 6.68 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 8.4 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 4.7 |
| Interleukin-2 signaling | R-HSA-451927 | 5.05 |
| MAP kinase activation in TLR cascade | R-HSA-450294 | 7.28 |
| truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 9.18 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 6.51 |
| misspliced GSK3beta mutants stabilize beta-catenin | R-HSA-5339716 | 9.08 |
| S33 mutants of beta-catenin aren't phosphorylated | R-HSA-5358747 | 9.08 |
| S37 mutants of beta-catenin aren't phosphorylated | R-HSA-5358749 | 9.08 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 6.73 |
| DAP12 interactions | R-HSA-2172127 | 4.56 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.71 |
| Signaling by ERBB2 | R-HSA-1227986 | 4.66 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 5.07 |
| Signaling by WNT in cancer | R-HSA-4791275 | 7.89 |
| ERK/MAPK targets | R-HSA-198753 | 8.59 |
| Immune System | R-HSA-168256 | 2.37 |
| Frs2-mediated activation | R-HSA-170968 | 5.12 |
| Downstream signal transduction | R-HSA-186763 | 4.65 |
| RAF activation | R-HSA-5673000 | 8.34 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 5.15 |
| T41 mutants of beta-catenin aren't phosphorylated | R-HSA-5358752 | 9.08 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 8.08 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 6.73 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 5.45 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 5.12 |
| CTLA4 inhibitory signaling | R-HSA-389513 | 8.52 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 5.14 |
| Cell Cycle, Mitotic | R-HSA-69278 | 4.16 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 5.14 |
| MyD88-independent TLR3/TLR4 cascade | R-HSA-166166 | 6.47 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 4.71 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 4.03 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 5.09 |
| Innate Immune System | R-HSA-168249 | 3.17 |
| Integration of energy metabolism | R-HSA-163685 | 6.24 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 5.36 |
| Mitotic Anaphase | R-HSA-68882 | 5.46 |
| NGF signalling via TRKA from the plasma membrane | R-HSA-187037 | 4.51 |
| Prolonged ERK activation events | R-HSA-169893 | 5.11 |
| Signaling by Wnt | R-HSA-195721 | 4.79 |
| Signaling by FGFR2 | R-HSA-5654738 | 4.68 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 10.18 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 5.15 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 6.72 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 6.73 |
| ERKs are inactivated | R-HSA-202670 | 9.4 |
| Axon guidance | R-HSA-422475 | 3.93 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 9.18 |
| Mitotic Prometaphase | R-HSA-68877 | 6.08 |
| TRIF-mediated TLR3/TLR4 signaling | R-HSA-937061 | 6.47 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 6.51 |
| Signaling by Leptin | R-HSA-2586552 | 5.1 |
| IGF1R signaling cascade | R-HSA-2428924 | 4.85 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 4.85 |
| M Phase | R-HSA-68886 | 4.87 |
| IRS-mediated signalling | R-HSA-112399 | 4.87 |
| Signaling by Insulin receptor | R-HSA-74752 | 4.73 |
| Disease | R-HSA-1643685 | 3.33 |
| Insulin receptor signalling cascade | R-HSA-74751 | 4.85 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 4.71 |
| Metabolism of carbohydrates | R-HSA-71387 | 4.93 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 4.26 |
| Toll-Like Receptors Cascades | R-HSA-168898 | 5.91 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 6.56 |
| Diseases of signal transduction | R-HSA-5663202 | 4.89 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 5.15 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 6.68 |
| Signalling to RAS | R-HSA-167044 | 5.08 |
| Glycolysis | R-HSA-70171 | 8.03 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 4.71 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 5.15 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 5.14 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 6.64 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 5.15 |
| Opioid Signalling | R-HSA-111885 | 6.64 |
| ARMS-mediated activation | R-HSA-170984 | 5.12 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 5.15 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 6.68 |
| MyD88:Mal cascade initiated on plasma membrane | R-HSA-166058 | 6.56 |
| Signaling by FGFR1 | R-HSA-5654736 | 4.69 |
| Signaling by PDGF | R-HSA-186797 | 4.53 |
| Activated TLR4 signalling | R-HSA-166054 | 6.27 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 6.62 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 4.85 |
| Separation of Sister Chromatids | R-HSA-2467813 | 5.55 |
| Signaling by Interleukins | R-HSA-449147 | 4.71 |
| Signaling by Rho GTPases | R-HSA-194315 | 4.43 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 3.74 |
| SOS-mediated signalling | R-HSA-112412 | 5.15 |
| Metabolism | R-HSA-1430728 | 2.34 |
| disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 8.03 |
| Signaling by ERBB4 | R-HSA-1236394 | 4.7 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 5.11 |
| Adaptive Immune System | R-HSA-1280218 | 3.19 |
| DARPP-32 events | R-HSA-180024 | 8.4 |
| MAPK family signaling cascades | R-HSA-5683057 | 4.89 |
| Signalling by NGF | R-HSA-166520 | 4.23 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 9.18 |
| Platelet sensitization by LDL | R-HSA-432142 | 8.89 |
| Costimulation by the CD28 family | R-HSA-388841 | 6.56 |
| Signaling by FGFR4 | R-HSA-5654743 | 4.69 |
| Signaling by FGFR3 | R-HSA-5654741 | 4.69 |
| RHO GTPases Activate Formins | R-HSA-5663220 | 6.01 |
| Signaling by FGFR | R-HSA-190236 | 4.67 |
| Signaling by SCF-KIT | R-HSA-1433557 | 4.73 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 4.9 |
| S45 mutants of beta-catenin aren't phosphorylated | R-HSA-5358751 | 9.08 |
| DAP12 signaling | R-HSA-2424491 | 4.64 |
| Interleukin-3, 5 and GM-CSF signaling | R-HSA-512988 | 4.99 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 6.18 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 7.66 |
| RHO GTPase Effectors | R-HSA-195258 | 4.94 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 5.14 |
| Signaling by GPCR | R-HSA-372790 | 2.68 |
| Signalling to ERKs | R-HSA-187687 | 5.04 |
| truncated APC mutants destabilize the destruction complex | R-HSA-4839744 | 9.18 |
| phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex | R-HSA-4839743 | 9.08 |
| AMER1 mutants destabilize the destruction complex | R-HSA-4839748 | 9.18 |
| Hemostasis | R-HSA-109582 | 3.98 |
| Signal Transduction | R-HSA-162582 | 1.78 |